RecruitingNot ApplicableNCT06984822

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

Evaluation of Serum and Ocular Coherence Tomography Biomarkers in Patients With Diabetic Macular Edema Treated With Anti-VEGF or Dexamethasone Implant

Sponsor

Vastra Gotaland Region

Enrollment

150 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus Oxidative Stress Hyperglycaemia (Diabetic)Diabetic Macular Edema Visual Impairment Vascular Endothelial Growth Factor VEGF

Summary

This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Anti-VEGF treatment, a medical device called Dexamethasone implant, and others for people with diabetes mellitus, diabetic macular edema, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.